25D-NBOMe (or NBOMe-2C-D) is a derivative of the
phenethylamine derived hallucinogen
2C-D
2C-D (2,5-dimethoxy-4-methylphenethylamine or 2C-M) is a psychedelic drug of the 2C family that is sometimes used as an entheogen. It was first synthesized in 1970 by a team from the Texas Research Institute of Mental Sciences, and its activity w ...
. It acts in a similar manner to related compounds such as
25I-NBOMe, which is a potent
agonist at the
5HT2A receptor
Receptor may refer to:
* Sensory receptor, in physiology, any structure which, on receiving environmental stimuli, produces an informative nerve impulse
*Receptor (biochemistry), in biochemistry, a protein molecule that receives and responds to a ...
. 25D-NBOMe has been sold as a street drug since 2010 and produces similar effects in humans to related compounds such as
25I-NBOMe and
25C-NBOMe. It was banned as a
Temporary Class Drug
A temporary class drug is a relatively new status for controlled drugs, which has been adopted in some jurisdictions, notably New Zealand and the United Kingdom, to attempt to bring newly synthesised designer drugs under legal control. The control ...
in the UK on 10 June 2013 after concerns about its recreational use.
Legality
China
As of October 2015 25D-NBOMe is a controlled substance in China.
Sweden
''Sveriges riksdag'' added 25D-NBOMe to schedule I (''"substances, plant materials and fungi which normally do not have medical use"'') as narcotics in Sweden as of Aug 1, 2013, published by
''Medical Products Agency'' in their regulation LVFS 2013:15 listed as 25D-NBOMe 2-(2,5-dimetoxi-4-metylfenyl)-N-(2-metoxibensyl)etanamin.
United Kingdom
United States
Unregulated at a federal and state level, though arguably may contravene the
Federal Analog Act
The Federal Analogue Act, , is a section of the United States Controlled Substances Act passed in 1986 which allows any chemical "substantially similar" to a controlled substance listed in Schedule I or II to be treated as if it were listed in ...
under certain circumstances given its structural and functional similarity to controlled substance 2C-D.
See also
*
25I-NBOMe (2C-I-NBOMe)
*
25B-NBOMe (2C-B-NBOMe)
*
25C-NBOMe (2C-C-NBOMe)
*
25E-NBOMe
25E-NBOMe (2C-E-NBOMe, NBOMe-2C-E) is a derivative of the phenethylamine 2C-E. It acts in a similar manner to related compounds such as 25I-NBOMe, which are potent agonists at the 5HT2A receptor. 25E-NBOMe has been sold as a drug and produces ...
(2C-E-NBOMe)
*
25N-NBOMe (2C-N-NBOMe)
*
25P-NBOMe
25P-NBOMe (2C-P-NBOMe, NBOMe-2C-P) is a derivative of the phenethylamine 2C-P. It acts in a similar manner to related compounds such as 25I-NBOMe, which are potent agonists at the 5HT2A receptor. 25P-NBOMe has been sold as a drug and produces s ...
(2C-P-NBOMe)
* 25G-NBOMe (2C-G-NBOMe)
* 25H-NBOMe (2C-H-NBOMe)
*
25TFM-NBOMe
25TFM-NBOMe (also known as NBOMe-2C-TFM, 2C-TFM-NBOMe, and Cimbi-138) is a derivative of the phenethylamine hallucinogen 2C-TFM, discovered in 2004 by Ralf Heim at the Free University of Berlin. It acts as a potent partial agonist for the 5HT2A ...
(2C-TFM-NBOMe)
References
25-NB (psychedelics)
Designer drugs
{{hallucinogen-stub